SCHEMBL1440326

SCHEMBL1440326

CCCNc1ncnc(Cl)c1F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
HTT P42858 2/20 0.45
POLB P06746 1/20 0.44
LMNA P02545 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
CCNC P24863 1/20 0.43
CDK8 P49336 1/20 0.43
RAF1 P04049 1/20 0.43
GALR3 O60755 1/20 0.40
CHRM4 P08173 1/20 0.39
RAB9A P51151 3/20 0.37
PDE10A Q9Y233 1/20 0.36
NPSR1 Q6W5P4 2/20 0.36
S1PR2 O95136 1/20 0.36
SRC P12931 1/20 0.35
KDM4E B2RXH2 4/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
BTK Q06187 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1439729 0.85 KDM4E (0.40) GALR3RAB9APDE10AKDM4EBTK
SCHEMBL4057859 0.79 GALR3 (0.61) ALDH1A1HTTPOLBLMNASMN1; SMN2
SCHEMBL1440229 0.75 PDPK1 (0.37) ALDH1A1LMNASMN1; SMN2GALR3HSD17B10
SCHEMBL23396724 0.73 TLR8 (0.37) ALDH1A1HTTLMNASMN1; SMN2MEN1
SCHEMBL20130427 0.72 POLB (0.56) ALDH1A1HTTPOLBLMNASMN1; SMN2
SCHEMBL28505552 0.70 SMN1; SMN2 (0.40) ALDH1A1HTTLMNASMN1; SMN2MEN1
SCHEMBL2629006 0.69 KDM4E (0.44) ALDH1A1HTTPOLBLMNASMN1; SMN2
SCHEMBL18519960 0.69 POLB (0.53) ALDH1A1HTTPOLBLMNASMN1; SMN2
SCHEMBL31320118 0.69 ABL1 (0.41) SRC
SCHEMBL23396651 0.69 MAPT (0.31) HTTPOLBLMNAGALR3RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112300172-B Bruton tyrosine kinase inhibitors 比奥根MA公司 2024-01-16 CN disclosed
US-20230046457-A1 BRUTON'S TYROSINE KINASE INHIBITORS BIOGEN MA INC. 2023-02-16 US disclosed
CN-112300172-A Bruton's tyrosine kinase inhibitors 比奥根MA公司 2021-02-02 CN disclosed
US-20200399283-A1 BRUTON'S TYROSINE KINASE INHIBITORS VIRACTA THERAPEUTICS, INC. 2020-12-24 US disclosed
CN-107011330-B Bruton's tyrosine kinase inhibitors 比奥根MA公司 2020-07-03 CN disclosed
US-10577374-B2 Bruton's tyrosine kinase inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2020-03-03 US disclosed
EP-3461824-A1 BRUTON'S TYROSINE KINASE INHIBITORS Biogen MA Inc. (US) 2019-04-03 EP disclosed
EP-2473049-B1 BRUTON'S TYROSINE KINASE INHIBITORS BIOGEN MA INC (US) 2018-11-28 EP disclosed
US-20180065974-A1 BRUTON'S TYROSINE KINASE INHIBITORS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2018-03-08 US disclosed
US-9790229-B2 Bruton's tyrosine kinase inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2017-10-17 US disclosed
US-20160376281-A1 BRUTON'S TYROSINE KINASE INHIBITORS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2016-12-29 US disclosed
US-9249146-B2 Bruton'S tyrosine kinase inhibitors BIOGEN MA INC. (US) 2016-02-02 US disclosed
US-20140309212-A1 BRUTON'S TYROSINE KINASE INHIBITORS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2014-10-16 US disclosed
US-8785440-B2 Bruton's tyrosine kinase inhibitors BIOGEN IDEC MA, INC. (US) 2014-07-22 US disclosed
EP-2473049-A1 BRUTON'S TYROSINE KINASE INHIBITORS Biogen Idec MA Inc. (US) 2012-07-11 EP disclosed
US-20120157443-A1 BRUTON'S TYROSINE KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. (US) 2012-06-21 US disclosed
WO-2011029046-A1 BRUTON'S TYROSINE KINASE INHIBITORS BIOGEN IDEC MA INC. (US) 2011-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230046457-A1 BRUTON'S TYROSINE KINASE INHIBITORS BTK, ABL1, SYK ALDH1A1 4783/4885HTT 3688/4885POLB 1897/4885
US-20160376281-A1 BRUTON'S TYROSINE KINASE INHIBITORS BTK, ABL1, SYK ALDH1A1 4783/4885HTT 3688/4885POLB 1897/4885
US-20140309212-A1 BRUTON'S TYROSINE KINASE INHIBITORS BTK, ABL1, SYK ALDH1A1 4783/4885HTT 3688/4885POLB 1897/4885
US-20200399283-A1 BRUTON'S TYROSINE KINASE INHIBITORS BTK, ABL1, SYK ALDH1A1 4783/4885HTT 3688/4885POLB 1897/4885
US-20120157443-A1 BRUTON'S TYROSINE KINASE INHIBITORS BTK, ABL1, SYK ALDH1A1 4783/4885HTT 3688/4885POLB 1897/4885
US-10577374-B2 Bruton's tyrosine kinase inhibitors BTK, ABL1, SYK ALDH1A1 4783/4885HTT 3688/4885POLB 1897/4885
US-20180065974-A1 BRUTON'S TYROSINE KINASE INHIBITORS BTK, ABL1, SYK ALDH1A1 4783/4885HTT 3688/4885POLB 1897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.